Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s European EPO Sales Unaffected By Biosimilars – For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

European biosimilars competing against first-generation erythropoietins, Amgen notes during Q3 earnings call.

You may also be interested in...

European Regulators Propose Hemoglobin Target Range For Anemia Therapies

Proposed EPO labeling that sets target hemoglobin levels in 10-12 g/dL range is consistent with European prescribing practices, analysts note.

Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products

EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.

EU’s CHMP Gives Nod To First Biosimilar Epoetin Alfa Formulations

Sandoz is set to launch its biosimilar, Binocrit, in 2007 following commission approval, the firm tells “The Pink Sheet” DAILY.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts